Market Cap | 44.15M | P/E | - | EPS this Y | 53.50% | Ern Qtrly Grth | - |
Income | -40.32M | Forward P/E | -1.92 | EPS next Y | 22.30% | 50D Avg Chg | -2.00% |
Sales | 2.78M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 6.00% |
Dividend | N/A | Price/Book | 1.74 | EPS next 5Y | - | 52W High Chg | -42.00% |
Recommedations | 1.70 | Quick Ratio | 4.97 | Shares Outstanding | 9.23M | 52W Low Chg | 131.00% |
Insider Own | 19.15% | ROA | -58.80% | Shares Float | 5.99M | Beta | 0.70 |
Inst Own | 33.88% | ROE | -122.49% | Shares Shorted/Prior | 30.23K/26.23K | Price | 0.84 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 240,174 | Target Price | 12.75 |
Oper. Margin | -3,876.95% | Earnings Date | Nov 12 | Volume | 14,557 | Change | 2.54% |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Oppenheimer | Outperform | Sep 12, 24 |
Chardan Capital | Buy | Sep 9, 24 |
Oppenheimer | Outperform | Aug 28, 24 |
Chardan Capital | Buy | Aug 12, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
Brookline Capital | Buy | Jun 7, 24 |
Chardan Capital | Buy | May 21, 24 |
HC Wainwright & Co. | Buy | May 21, 24 |
HC Wainwright & Co. | Buy | Apr 16, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Sullivan Eddie Joe | Chief Executive Offi.. Chief Executive Officer | Dec 07 | Buy | 0.88 | 1,740 | 1,531 | 5,232,304 | 12/08/23 |
King Michael | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Nov 30 | Buy | 0.900 | 5,000 | 4,500 | 5,000 | 11/30/23 |
HAMILTON CHRISTINE E | Director Director | Sep 13 | Buy | 0.7297 | 10,000 | 7,297 | 4,993,090 | 09/14/22 |
Sullivan Eddie Joe | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Sep 07 | Buy | 0.7368 | 14,000 | 10,315 | 5,230,564 | 09/08/22 |